Every now and I then I try to take some time to think about the focus of this blog and the direction it is going. In the most recent case, I got the feeling that perhaps I have giving too discouraged or negative an impression on the blog lately….focusing too much on the challenges and […]
Why I am very optimistic about the future of the stem cell field Read More »
When you want to both know the real history of the pluripotent stem cell-based biotech industry and perspectives on its future, there are only a handful of people to turn to and one of them is definitely Dr. Michael West, CEO of BioTime. I’m doing a several part series of blog posts on a lengthy
BioTime CEO Mike West Interview Part 2: Geron & hESC Read More »
There are a few excellent stem cell blogs out there. I can see two main ways to evaluate blogs. The first and most important in my opinion is qualitative. Do you enjoy the blog? Does it have fresh, original, & interesting content? Is it influential? I also look for a sense of humor and a
Top Stem Cell Blogs List & Their Internet Metrics Read More »
Is a treatment based on stem cells for Parkinson’s Disease on the horizon? A Japanese team of researchers led by Dr. Jun Takahashi, professor at Kyoto University is reportedly aiming to start on human studies of an induced pluripotent stem (iPS) cell-based treatment for Parkinson’s Disease (PD) as early as fiscal year (FY) 2014. In
Trial of Stem Cells for Parkinson’s Disease on Horizon Read More »
Cellular Dynamics, the stem cell company founded by Dr. James Thomson, is filing for an IPO. Hat tip to David Jensen. The company, which will go under the stock symbol ICEL, is focused on iPS cell-produced products. They describe their portfolio as follows: Cellular Dynamics is developing and deploying a number of cell types derived from
Cellular Dynamics IPO: big money, iPS cell IP rights, trade secrets Read More »
One of my favorite stem cell scientists is Jeanne Loring of Scripps. She does great science and when you ask her questions, she frankly states her opinions and is clearly a gifted educator at heart too. Below is a Q&A interview I did with Jeanne on key issues of clinical translation of iPS cells. You
Jeanne Loring interview: optimism on clinical translation of IPS cells Read More »
One of the more exciting stem cell biotechs out there today is Advanced Cell Technology (ACT). At this time ACT has the only two ES cell-based FDA-approved clinical trials ongoing and so far they have looked quite promising in terms of preliminary safety data. However, ACT has much more in the pipeline including potentially iPS
Interview with Gary Rabin of Advanced Cell Technology (ACT) Read More »
A relatively newly recognized, important player in the stem cell field is a molecule called histone H3.3. Histones are key components of chromatin with integral roles in regulating almost all aspects of cell behavior through orchestrating functions such as transcription and chromosome segregation. Histone H3.3 knockout My lab has just (April 9) published new studies
Histone H3.3: giving cells epigenetic flexibility Read More »
I’ve been fortunate to interview some of the greats in the stem cell field for this blog and host debates between key players. Please note that just because I have interviewed folks does not mean I agree with them or that they agree with me. The point is to establish dialogue on key issues. As
Interviews with leaders and top players in the stem cell field Read More »
One of my inspirations as a stem cell blogger was the pioneering Nature blog, the Niche. I was disappointed when it ended in 2009, but it still is a model of what excellence in science blogging is all about. In this piece today, I interview the co-Founder of the Niche, Dr. Natalie DeWitt. DeWitt now
Interview with Natalie DeWitt, Founder of Nature’s pioneering stem cell blog, the Niche Read More »